A Study to Evaluate Botulinum Toxin Type A for Injection（HengLi®）for Prophylactic Treatment of Chronic Migraine
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
A study, multi-center, randomized, double-blind, placebo parallel-controlled method, will be
carried out to evaluate the safety and efficacy of Botulinum Toxin Type A for injection
(HengLi®) for prophylactic treatment with chronic migraine in adults. In the core phase, two
treatments of HengLi® or the placebo will be administrated (randomized at a ratio of 2:1, the
target number is 288 subjects). In the extension phase, three treatments of HengLi® will be
still administrated on 288 subjects recruited ever.
Phase:
Phase 3
Details
Lead Sponsor:
Lanzhou Institute of Biological Products Co., Ltd
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA